Sign In
Buy CTXR
$0.570
-0.0620 (-9.81%)
At Close: Jul 31, 2026
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
08:37am, Friday, 21'st Nov 2025
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch CRANFORD, N.J. , Nov. 21, 20
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Growth in Short Interest
01:27am, Sunday, 02'nd Nov 2025
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR - Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 1,580,000 shares
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
04:30pm, Tuesday, 21'st Oct 2025
CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercializa
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
08:00am, Tuesday, 21'st Oct 2025
CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercializa
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
05:00pm, Friday, 17'th Oct 2025
LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J. , Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceu
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
08:47am, Thursday, 16'th Oct 2025
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J. , Oct. 16, 2025 /PRNewswire
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
04:30pm, Wednesday, 10'th Sep 2025
CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTX
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
08:47am, Friday, 22'nd Aug 2025
Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J. , Aug. 22, 2025 /PRNewswire/ -- Citi
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
04:30pm, Tuesday, 12'th Aug 2025
$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful mar
Citius Oncology Announces Closing of $9.0 Million Public Offering
04:30pm, Thursday, 17'th Jul 2025
CRANFORD, N.J. , July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), to
Citius Oncology Announces Pricing of $9.0 Million Public Offering
09:15am, Wednesday, 16'th Jul 2025
CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), to
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
08:32am, Tuesday, 15'th Jul 2025
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J. , July 15, 2025 /PRN
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:34am, Tuesday, 08'th Jul 2025
CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
08:08am, Tuesday, 17'th Jun 2025
CRANFORD, N.J. , June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTX
